Hyperlipidemia Drugs Market Size, Share, and Trends 2025 to 2034

The global hyperlipidemia drugs market size is calculated at USD 23.85 billion in 2025, and is predicted to hit around USD 33.94 billion by 2034, poised to grow at a CAGR of 4% between 2025 and 2034. The Europe hyperlipidemia drugs market size accounted for USD 10.32 billion in 2024 and is anticipated to grow at the fastest CAGR of 4.11% during the forecast year. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.

Last Updated : May 2025  |  Report Code : 3408  |  Category : Healthcare  |  Format : PDF / PPT / Excel

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Hyperlipidemia Drugs Market 

5.1. COVID-19 Landscape: Hyperlipidemia Drugs Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Hyperlipidemia Drugs Market, By Drug Class

8.1. Hyperlipidemia Drugs Market Revenue and Volume, by Drug Class

8.1.1. Statins

8.1.1.1. Market Revenue and Volume Forecast 

8.1.2. Bile Acid Sequestrants

8.1.2.1. Market Revenue and Volume Forecast 

8.1.3. Cholesterol Absorption Inhibitors

8.1.3.1. Market Revenue and Volume Forecast

8.1.4. Fibric Acid Derivatives

8.1.4.1. Market Revenue and Volume Forecast 

8.1.5. PCSK9 Inhibitors

8.1.5.1. Market Revenue and Volume Forecast 

8.1.6. Combination

8.1.6.1. Market Revenue and Volume Forecast 

8.1.7. Miscellaneous

8.1.7.1. Market Revenue and Volume Forecast 

Chapter 9. Global Hyperlipidemia Drugs Market, By Route of Administration

9.1. Hyperlipidemia Drugs Market Revenue and Volume, by Route of Administration

9.1.1. Oral

9.1.1.1. Market Revenue and Volume Forecast

9.1.2. Parenteral

9.1.2.1. Market Revenue and Volume Forecast

9.1.3. Others

9.1.3.1. Market Revenue and Volume Forecast 

Chapter 10. Global Hyperlipidemia Drugs Market, Regional Estimates and Trend Forecast

10.1. North America

10.1.1. Market Revenue and Volume Forecast, by Drug Class 

10.1.2. Market Revenue and Volume Forecast, by Route of Administration 

10.1.3. U.S.

10.1.3.1. Market Revenue and Volume Forecast, by Drug Class 

10.1.3.2. Market Revenue and Volume Forecast, by Route of Administration

10.1.4. Rest of North America

10.1.4.1. Market Revenue and Volume Forecast, by Drug Class

10.1.4.2. Market Revenue and Volume Forecast, by Route of Administration 

10.2. Europe

10.2.1. Market Revenue and Volume Forecast, by Drug Class

10.2.2. Market Revenue and Volume Forecast, by Route of Administration 

10.2.3. UK

10.2.3.1. Market Revenue and Volume Forecast, by Drug Class 

10.2.3.2. Market Revenue and Volume Forecast, by Route of Administration

10.2.4. Germany

10.2.4.1. Market Revenue and Volume Forecast, by Drug Class 

10.2.4.2. Market Revenue and Volume Forecast, by Route of Administration 

10.2.5. France

10.2.5.1. Market Revenue and Volume Forecast, by Drug Class 

10.2.5.2. Market Revenue and Volume Forecast, by Route of Administration 

10.2.6. Rest of Europe

10.2.6.1. Market Revenue and Volume Forecast, by Drug Class 

10.2.6.2. Market Revenue and Volume Forecast, by Route of Administration 

10.3. APAC

10.3.1. Market Revenue and Volume Forecast, by Drug Class

10.3.2. Market Revenue and Volume Forecast, by Route of Administration

10.3.3. India

10.3.3.1. Market Revenue and Volume Forecast, by Drug Class

10.3.3.2. Market Revenue and Volume Forecast, by Route of Administration 

10.3.4. China

10.3.4.1. Market Revenue and Volume Forecast, by Drug Class 

10.3.4.2. Market Revenue and Volume Forecast, by Route of Administration

10.3.5. Japan

10.3.5.1. Market Revenue and Volume Forecast, by Drug Class 

10.3.5.2. Market Revenue and Volume Forecast, by Route of Administration

10.3.6. Rest of APAC

10.3.6.1. Market Revenue and Volume Forecast, by Drug Clas

10.3.6.2. Market Revenue and Volume Forecast, by Route of Administration

10.4. MEA

10.4.1. Market Revenue and Volume Forecast, by Drug Class 

10.4.2. Market Revenue and Volume Forecast, by Route of Administration 

10.4.3. GCC

10.4.3.1. Market Revenue and Volume Forecast, by Drug Class

10.4.3.2. Market Revenue and Volume Forecast, by Route of Administration 

10.4.4. North Africa

10.4.4.1. Market Revenue and Volume Forecast, by Drug Class

10.4.4.2. Market Revenue and Volume Forecast, by Route of Administration 

10.4.5. South Africa

10.4.5.1. Market Revenue and Volume Forecast, by Drug Class 

10.4.5.2. Market Revenue and Volume Forecast, by Route of Administration

10.4.6. Rest of MEA

10.4.6.1. Market Revenue and Volume Forecast, by Drug Class

10.4.6.2. Market Revenue and Volume Forecast, by Route of Administration 

10.5. Latin America

10.5.1. Market Revenue and Volume Forecast, by Drug Class

10.5.2. Market Revenue and Volume Forecast, by Route of Administration

10.5.3. Brazil

10.5.3.1. Market Revenue and Volume Forecast, by Drug Class 

10.5.3.2. Market Revenue and Volume Forecast, by Route of Administration

10.5.4. Rest of LATAM

10.5.4.1. Market Revenue and Volume Forecast, by Drug Class 

10.5.4.2. Market Revenue and Volume Forecast, by Route of Administration 

Chapter 11. Company Profiles

11.1. F. Hoffmann-La Roche Ltd. (Switzerland)

11.1.1. Company Overview

11.1.2. Product Offerings

11.1.3. Financial Performance

11.1.4. Recent Initiatives

11.2. Mylan N.V. (U.S.)

11.2.1. Company Overview

11.2.2. Product Offerings

11.2.3. Financial Performance

11.2.4. Recent Initiatives

11.3. Teva Pharmaceutical Industries Ltd. (Israel)

11.3.1. Company Overview

11.3.2. Product Offerings

11.3.3. Financial Performance

11.3.4. Recent Initiatives

11.4. Sanofi (France)

11.4.1. Company Overview

11.4.2. Product Offerings

11.4.3. Financial Performance

11.4.4. Recent Initiatives

11.5. Pfizer Inc. (U.S.)

11.5.1. Company Overview

11.5.2. Product Offerings

11.5.3. Financial Performance

11.5.4. Recent Initiatives

11.6. GlaxoSmithKline plc (UK)

11.6.1. Company Overview

11.6.2. Product Offerings

11.6.3. Financial Performance

11.6.4. Recent Initiatives

11.7. Novartis AG (Switzerland)

11.7.1. Company Overview

11.7.2. Product Offerings

11.7.3. Financial Performance

11.7.4. Recent Initiatives

11.8. AstraZeneca (U.K.)

11.8.1. Company Overview

11.8.2. Product Offerings

11.8.3. Financial Performance

11.8.4. Recent Initiatives

11.9. Johnson & Johnson Private Limited (U.S.)

11.9.1. Company Overview

11.9.2. Product Offerings

11.9.3. Financial Performance

11.9.4. Recent Initiatives

11.10. Sun Pharmaceutical Industries Ltd. (India)

11.10.1. Company Overview

11.10.2. Product Offerings

11.10.3. Financial Performance

11.10.4. Recent Initiatives

Chapter 12. Research Methodology

12.1. Primary Research

12.2. Secondary Research

12.3. Assumptions

Chapter 13. Appendix

13.1. About Us

13.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

The global hyperlipidemia drugs market size is expected to increase USD 33.94 billion by 2034 from USD 22.93 billion in 2024.

The global hyperlipidemia drugs market will register growth rate of 4% between 2025 and 2034.

The major players operating in the hyperlipidemia drugs market are F. Hoffmann-La Roche Ltd., Mylan N.V., Teva Pharmaceutical Industries Ltd., Sanofi, Pfizer Inc., GlaxoSmithKline plc, Novartis AG, AstraZeneca, Johnson & Johnson Private Limited, Sun Pharmaceutical Industries Ltd, Bristol-Myers Squibb Company, Eli Lilly and Company, Regeneron Pharmaceuticals Inc., Amgen Inc., DAIICHI SANKYO COMPANY, LIMITED, Alnylam Pharmaceuticals, Inc, Dr. Reddy's Laboratories Ltd., Esperion Therapeutics, Inc, and Others.

The driving factors of the hyperlipidemia drugs market are the increasing prevalence of hyperlipidemia and the demand for lipid-regulating medications has surged.

Europe region will lead the global hyperlipidemia drugs market during the forecast period 2025 to 2034.

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client